A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04082936 |
Recruitment Status :
Active, not recruiting
First Posted : September 10, 2019
Last Update Posted : November 15, 2023
|
Sponsor:
IGM Biosciences, Inc.
Collaborator:
ADC Therapeutics S.A.
Information provided by (Responsible Party):
IGM Biosciences, Inc.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Active, not recruiting |
---|---|
Estimated Primary Completion Date : | October 2024 |
Estimated Study Completion Date : | October 2024 |